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Abstract 
Hepatocellular carcinoma (HCC) is a common cancer with high mortality. The limited 
therapeutic options for advanced disease include treatment with Sorafenib, a multi-
kinase inhibitor whose targets include the Mediator kinase CDK8. Since CDK8 has 
reported oncogenic activity in Wnt-dependent colorectal cancer, we investigated 
whether it is also involved in HCC. We find that CDK8 and its paralogue CDK19 are 
significantly overexpressed in HCC patients, where high levels correlate with poor 
prognosis. Liver-specific genetic deletion of CDK8 in mice is well supported and 
protects against chemical carcinogenesis. Deletion of either CDK8 or CDK19 in hepatic 
precursors had little effect on gene expression in exponential cell growth but prevented 
oncogene-induced transformation. This phenotype was reversed by concomitant 
deletion of TP53. These data support important and non-redundant roles for mediator 
kinases in liver carcinogenesis, where they genetically interact with the TP53 tumor 
suppressor. 
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Introduction 
The cyclin-dependent kinase CDK8 is the principal catalytic subunit of the 
Mediator complex kinase module (1). In mice, genetic deletion of CDK8 or its activating 
subunit, cyclin C, is embryonic lethal (2, 3). Vertebrate genomes encode a second 
paralogue of CDK8, CDK19, which also binds cyclin C and can replace CDK8 in the 
kinase module of Mediator (4, 5). CDK8 may act as an oncogene in several tumor 
types, including melanoma and colorectal cancer (CRC) (6, 7). Amplification of the 
CDK8 gene was found in 14% of CRC patients, and reversing CDK8 over-expression 
in CRC cells with amplified CDK8 reduced cell proliferation by interfering with the β-
catenin pathway (6, 8). CDK8 was also uncovered in a mouse transposon-mediated 
mutagenesis screen for genes whose alteration contributes to intestinal cancer (9). 
However, intestine-specific Cdk8 deletion in mice failed to confirm an oncogenic role 
in intestinal tumorigenesis triggered by mutation of the tumor suppressor Apc ((10), 
and our unpublished results).  
CDK8 acts as a co-factor of many transcriptional activators and participates in 
regulating the expression of a large number of genes, including immediate early genes 
(11–14), targets of β-catenin (6), p53 (15), c-Myc (16), Hypoxia-inducible factor 1a 
(HIF1a) (17, 18), Nuclear-factor kappa B (NFkB) (19) and Notch1 (3, 20). CDK8 
expression appears to maintain tumors in an undifferentiated state by regulating c-Myc 
programmes (16). CDK8 was  also identified as a crucial regulator of tumor-promoting 
activity of senescent cells (21). It is presently unclear how these multiple pathways 
participate in tumor promotion by CDK8, and whether its paralogue CDK19 has similar 
roles in tumorigenesis. 
Since the oncogenic roles of CDK8 in Wnt-dependent CRC have been well 
documented in the context of constitutive Wnt signalling, we wondered whether it also 
has roles in hepatocellular carcinoma (HCC), another tumor type frequently associated 
with activation of Wnt/β-catenin signalling (22). HCC is the main primary liver tumor 
and one of the most deadly cancers worldwide (23). Mutations in the CTNNB1 gene, 
coding for β-catenin, are found in around 30% of patients and are mainly associated 
with the well differentiated, less aggressive, class of HCC (groups G5 - G6) (22, 24). 
CDK8 is expressed in the liver, where it may regulate lipogenesis (25). Importantly, 
lipid accumulation as well as de novo lipid biosynthesis and the resulting lipotoxicity 
lead to hepatic inflammation, constituting major risk factors for liver tumorigenesis (22).  
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In this study, we show that although CDK8 has a limited role in liver homeostasis 
both CDK8 and CDK19 paralogues are required for hepatic carcinogenesis in the 
context of wild-type p53. 
 
Results 
 
CDK8 and CDK19 are highly expressed in p53-mutated hepatocellular carcinoma 
To test whether expression of CDK8 or that of its paralogue CDK19 is altered in 
hepatic carcinogenesis, we first quantified by qRT-PCR their expression in a large 
cohort of HCC patients (n=268, Supplemental Table 1). We found that both CDK8 and 
CDK19 are significantly overexpressed in HCC tumors compared to non-tumoral 
counterparts or normal liver (Figure 1A). Moreover, we detected a correlation between 
the expression of the two kinases in HCC (Figure 1B), as previously observed in breast 
cancer (26). Analysis revealed no correlation with a specific aetiology (alcohol, viral 
infection, metabolic syndrome). However, there was a highly significant difference in 
CDK8/19 expression among the HCC subgroups defined by the classification based 
on clinical and molecular features (24, 27): CDK8 or CDK19 high expressors were 
enriched in the aggressive G1-G3 subsets as compared to G4-G6 (Figure 1C). 
Coherently, high CDK8 or CDK19 expression was correlated with mutant p53 status, 
molecular prognostic 5-gene score (28) and macroscopic vascular invasion (Figure 
1D, E and F). Finally, high level expression of CDK8 or CDK19 correlated with poor 
prognosis (Figure 1G). Thus our data are consistent with an oncogenic role for 
Mediator kinases in hepatocellular carcinoma. 
 
CDK8 is dispensable for liver homeostasis 
To investigate possible roles of the Mediator kinases in liver function and hepatic 
carcinogenesis, we focused on CDK8. We generated a genetically modified mouse 
with loxP sites flanking exon 2 of the Cdk8 gene (Figure 2A). Crossing these animals 
with transgenic mice expressing the Cre recombinase under the control of the Albumin 
promoter (Alb-Cre mice(29)) gives rise to hepatocyte-specific deletion of the essential 
exon 2, and induces a frameshift that results in a stop codon at position 52, eliminating 
CDK8 protein in the liver (CDK8Δhep animals) (Figure 2B).  
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In accordance with the absence of overt phenotype of ubiquitous Cdk8 deletion 
in adult animals (10), the liver-specific deletion of CDK8 was compatible with normal 
liver development and we detected no change in liver physiology at the age of 3 months 
(Figure 2C). Importantly, the β-catenin-driven metabolic liver zonation was not affected 
by the CDK8 ablation, as judged by the purely centrilobular expression of glutamine 
synthetase (Figure 2C). Moreover, we detected no differences in the expression levels 
of several β-catenin target genes between the control and the CDK8Δhep animals 
(Figure 2C). These results indicate that CDK8 is not required to regulate the β-catenin 
pathway under normal homeostasis conditions. However, in aging animals (> 6 
months) CDK8 deficiency led to increased body weight and higher liver steatosis score 
(Figure 2D), confirming an involvement of CDK8 in liver lipogenesis (25). Older 
CDK8Δhep animals (12-15 months) did not show any sign of liver tumors (n= 12). 
 
CDK8 is required for chemically induced liver carcinogenesis and hepatic cell 
transformation 
We next used a model of hepatic carcinogenesis in CDK8Δhep animals to 
investigate potential roles of CDK8 in liver cancer. In this model, a single injection of 
hepatotoxic agent diethylnitrosamine (DEN) to young mice gives rise to liver tumors 
after 6-8 months (30). We sacrificed DEN-treated animals at 28 weeks, a relatively 
early time point in the kinetics of tumor formation, to allow detection of both positive 
and negative changes in tumor burden. As expected, 9 out 17 (53%) of the control 
Cdk8F/F mice had at least one macroscopic liver tumor at sacrifice (Figure 3A). In 
contrast, only one out of eleven (9%) CDK8Δhep animals had developed tumors by this 
time point. Cell death and regenerative response of the livers shortly after the DEN 
treatment were both indistinguishable between controls and CDK8Δhep mice 
(Supplemental Figure 1), indicating that CDK8 ablation acted by inhibiting 
tumorigenesis rather than by interfering with the initial hepatoxicity of the treatment. 
Taken together, these data support the hypothesis that CDK8 contributes to 
chemically-induced liver carcinogenesis in mice. 
To investigate whether the effects of CDK8 loss on carcinogenesis were cell 
autonomous, we next isolated primary hepatic progenitor cells (BMEL) (31) from 
Cdk8F/F embryos. Upon stable transfection of Cre, we obtained an efficient deletion of 
CDK8 from these cells (Figure 3B). CDK8 loss had no effect on BMEL cell morphology 
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or growth characteristics under standard monolayer culture conditions (Figure 3B). As 
murine liver tumors triggered by DEN injection are often driven by mutated forms of 
Ras (30), we used forced expression of an oncogenic form of Ras, H-RasG12V, to 
investigate effects of CDK8 loss on hepatic cell transformation. Similarly to previous 
results obtained with independent BMEL cell lines (32), H-RasG12V was sufficient to 
transform primary Cdk8F/F BMEL cells, which then efficiently formed colonies in soft 
agar (Figure 3C). In contrast, CRE-mediated deletion of CDK8 abolished colony 
formation in this assay (Figure 3C), which is consistent with the protective role of CDK8 
deletion in DEN-treated livers. Next, we used a model of tamoxifen-inducible CreERT2 
activation. This confirmed the CDK8 requirement for Ras-induced transformation. 
Strikingly, deletion of CDK8 in cells previously transformed by RasG12V expression 
reverted their transformed phenotype (Figure 3C). To validate in vivo that CDK8 
deletion protects hepatic progenitors from Ras-induced transformation, we injected 
CDK8F/F RasG12V or CDK8-/- RasG12V BMEL cells into the liver of immunodeficient mice. 
While the Cdk8F/F BMEL expressing RasG12V gave rise to orthotopic tumors, their 
counterparts devoid of CDK8 did not (Figure 3D).  
We next disrupted Cdk8 by by CRISPR/Cas9-mediated gene disruption, wich 
confirmed both the absence of apparent phenotype in CDK8-depleted cells and the 
requirement for CDK8 for cell transformation (Figure 3E). Finally, to exclude that the 
requirement for CDK8 for transformation is specific for BMEL cells, we disrupted it by 
CRISPR/Cas9 in a human hepatoblastoma cell line, HepG2. As expected, the cells 
grew well in the absence of CDK8, but again did not form colonies in soft agar (Figure 
3E). Altogether, our results indicate that CDK8 is required for H-RasG12V-driven 
oncogenic transformation of hepatocytes and of hepatic progenitor cells.  
 
CDK8 deletion impairs RasG12V-driven transformation in a p53-dependent 
manner 
We then investigated possible molecular mechanisms by which CDK8 removal 
could impair RasG12V-driven transformation. Deletion of CDK8 did not abrogate 
RasG12V-induced cell shape remodelling or ERK phosphorylation (Supplemental Figure 
2A, B), indicating that the kinase is dispensable for Ras pathway activation. Second, 
constitutive activation of the β-catenin pathway in the BMEL cells did not rescue CDK8 
deficiency (Supplemental Figure 2C), indicating that tumor-promoting activity of CDK8 
in the liver does not rely on the activation of the β-catenin pathway, which is consistent 
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with the lack of β-catenin-related phenotype in CDK8Δhep livers (Figure 2). Third, CDK8 
has been proposed as a regulator of glycolysis (33), and we therefore tested whether 
CDK8 removal affects the metabolism of BMEL cells. However, analysis of glycolysis 
(Seahorse Glycolysis stress test) and mitochondrial respiration (Seahorse Mito stress 
test) did not reveal any effect of CDK8 ablation (Supplemental Figure 3), indicating that 
this regulation is not present in hepatic progenitor cells and that it does not account for 
the failure of CDK8-mutant cells to grow in soft agar. 
Since CDK8 overexpression in patients correlates with mutant p53 status, we 
next considered the possibility that CDK8 acts by modulating p53 function. Although 
CDK8 can act as a coactivator of the p53 transcriptional program (34), we observed 
that removal of CDK8 rather increases the level of p53 protein (Figure 4A), suggesting 
that CDK8 might restrain the tumor-suppressive functions of p53 in hepatic cells. In 
agreement with this idea, soft agar tests showed that the requirement for CDK8 in Ras-
induced transformation was abrogated by p53 inactivation via CRISPR/Cas9 editing 
(Figure 4B). Furthermore, depletion of CDK8 did not prevent transformation of the p53-
deficient Huh7 cell line (Supplemental Figure 4). To extend these results to an in vivo 
setting, we triggered tumorigenesis via hydrodynamic gene delivery (HGD) (35) of  the 
activated form of Ras together with CRISPR/Cas9-mediated inactivation of 
endogenous p53. HGD with Ras alone did not generate tumors, as previously 
described (36), whereas simultaneous transfection with N-RasG12D and CRISPR-p53 
gave rise to multiple aggressive tumors within 4 weeks (Figure 4C). Consistent with 
the results of the cellular models, this combination of oncogenic stimuli was also fully 
efficient in CDK8Δhep animals, whose hepatocytes are devoid of CDK8 (Figure 4C). Cell 
lines derived from CDK8F/F or CDK8-/- HGD-tumors were equally capable of giving rise 
to tumors when injected orthotopically into immunocompetent mice (Figure 4D). Our 
results suggest that CDK8 is required for initiation of tumorigenesis by counteracting 
p53 function. 
 
Both CDK8 and CDK19 are required for RasG12V-driven transformation  
An interesting inference from the above results is that CDK19, whose 
expression is preserved in CDK8-deleted cells (Figure 5A), is insufficient to 
compensate for loss of CDK8, despite its high homology and redundant roles in 
Mediator. Furthermore, both CDK8 and CDK19 are overexpressed in a significant 
number of HCC patients. We therefore wondered whether CDK19 is also required for 
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Ras-induced tumorigenesis. To test this, we deleted CDK19 in BMEL cells by CRISPR-
Cas9 editing. The resulting mutant cells had unaltered morphology and proliferation 
kinetics (Figure 5A). Interestingly, CDK19 removal caused a significant upregulation of 
CDK8 protein levels, but not of mRNA levels, indicating a posttranscriptional feedback 
regulation of CDK8 in the absence of CDK19 (Figure 5A). 
Similarly to CDK8 deletion, CDK19 ablation prevented the acquisition of the 
transformed phenotype upon ectopic expression of the oncogenic form of Ras, as 
judged by the lack of anchorage-independent growth (Figure 5B). Again, we obtained 
similar results upon CDK19 deletion in human HepG2 cells (Supplemental Figure 4). 
Thus, both CDK8 and CDK19 are required for Ras-driven transformation of primary 
hepatic progenitors, neither paralogue being able to compensate for the absence of 
the other.  
As CDK8 and CDK19 constitute the only members of the CDK module 
regulating transcriptional activity of the mediator complex, one hypothesis to account 
for the requirement of simultaneous presence of both kinases is that they control 
different subsets of target genes, both of which are needed for transformation by H-
RasG12V. To test this hypothesis, we analyzed gene expression profiles of the Ras-
expressing BMEL cells in the presence or absence of CDK8 or CDK19 by RNA-seq 
(Figure 5C). Surprisingly, disruption of either CDK8 or CDK19 had only minor effects 
on gene expression, with only around 30 genes reproducibly showing more than 2-fold 
differences in expression between cells expressing RasG12V with or without deletion of 
Cdk8 or Cdk19. At this threshold of fold-change, we did not identify common genes 
deregulated by the absence of either kinase (Figure 5D). However, even though 
neither CDK8-/- nor CDK19-/- cells can be transformed by the oncogenic form of Ras, 
RasG12V caused deregulation of over 1000 genes, irrespective of the status of Cdk8 
and Cdk19 when growing in exponential culture, explaining their indistinguishable 
morphology. This result further shows that, despite the importance of Mediator for gene 
regulation, neither CDK8 nor CDK19 are required for implementing wide-ranging 
changes to gene expression, suggesting that their effects in carcinogenesis, which 
involve p53, are not due to major transcriptional changes. 
Discussion 
Combining patient data and mouse models, we provide evidence that both 
Mediator kinases, CDK8 and CDK19, are involved in hepatocellular carcinoma. Our 
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data indicate that these CDKs are required for initiation of tumorigenesis induced by 
mutation of a strong oncogene, Ras. To our knowledge, this is the first indication that 
the CDK8 paralogue CDK19 is required for cell transformation, indicating non-
redundant functions for both kinases in facilitating tumorigenesis.  
We find that removal of CDK8 in hepatocytes has no major consequences for 
liver functions, as previously indicated by the ubiquitous inactivation of the kinase in 
adult animals (10). However, we observed that CDK8 depletion induces steatosis in 
aging animals, in accordance with a role for the kinase as repressor of lipogenesis 
(25). In contrast to its mild effects on liver physiology, CDK8 disruption has a strong 
impact on hepatic carcinogenesis. We observed a major reduction of chemically 
induced tumorigenesis, and a complete protection from Ras-induced cell 
transformation. This requirement is further highlighted by the fact that CDK8 ablation 
occurring after RasG12V-induced transformation is able to restore the non-transformed 
phenotype.  
CDK8 thus apparently has diverse context-specific involvement in various 
cancers. CDK8 was initially described to have oncogenic properties in Wnt-dependent 
colorectal cancers, where it controls the beta-catenin pathway (6, 8) and maintains 
Myc functions (37). However, this was not confirmed genetically in mouse models; 
indeed, if anything, CDK8 knockout marginally increased progression from early 
lesions to tumors (10). A recent study also found no effect of CDK8 knockdown on 
growth of colorectal tumors in syngeneic mice, but it prevented liver metastases (38). 
Furthermore, CDK8 promotes proliferation of melanoma cell lines (7) and is apparently 
required for efficient Estrogen Receptor (ER)-dependent transcription in ER-positive 
breast cancer cells (39). However, most reports of anti-tumor activity caused by 
interfering with CDK8 function have used kinase inhibitors  (39–45) that target both 
CDK8 and CDK19. The most likely explanation for this is that CDK inhibitors are rarely 
very specific for one kinase subfamily (46) and some “CDK8/19 inhibitors” may inhibit 
other kinases required for efficient tumor development. This highlights the need for a 
genetic approach in vivo. 
Other studies have suggested that as well as possessing oncogenic activity in 
some contexts, CDK8 may rather have tumor-suppressive activity in others, including 
endometrial cancers (47), intestinal cancer (10) and T-cell acute lymphoblastic 
leukemia (3). 
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One way of reconciling these apparently different roles for Mediator kinases is 
to invoke possible tissue-specificity of action. We found that CDK8 deletion has no 
effect on hepatic cell growth, contrary to certain melanoma or gastric cancer cell lines, 
in which decrease of proliferation has been described (7, 48). Tissue specificity is 
further demonstrated by the fact that while knockout of either kinase is well tolerated 
by hepatic precursor cells, germline-deletion of the Cdk8 gene in mice is lethal at pre-
implantation embryogenic stages (2). Our results suggest that oncogenic activities of 
CDK8 and CDK19 in HCC are independent of the b-catenin pathway, and therefore 
likely operate through different mechanisms in colorectal and hepatic carcinogenesis. 
One key finding of our study is that both CDK8 and CDK19 are required for cell 
transformation by H-RasG12V. This is not due to downregulation of one kinase when the 
other one is removed, as, on the contrary, we found that CDK19 depletion stabilizes 
CDK8 protein, identifying a post transcriptional regulation of CDK8 levels. Of note, this 
cross-regulation is not bidirectional, as removal of CDK8 does not seem to stabilize 
CDK19 protein. A possible explanation for these results might be that CDK8 and 
CDK19 regulate transcription of specific gene sets that are both required for hepatic 
cell transformation. The results of our RNA-seq analysis renders this hypothesis 
unlikely, as very few genes are differentially transcribed in either knockout. However, 
we cannot exclude this entirely, as 12 genes were differentially regulated in knockouts 
of both Cdk8 and Cdk19 when the threshold for fold-change is removed: Adora1, Nt5e, 
Fgfbp1, Spp1, Gm5781, Lgals4, Rpl10-ps3, Akap12, Gm8349, Anxa10, Scd1, Ly6a. 
Yet the magnitude of the gene expression change is likely too low to be biologically 
meaningful; the regulation of several, including Anxa10 (encoding Annexin 10A), 
Akap12 (encoding A Kinase Anchoring Protein-12) and Nt5e (encoding 5’ 
nucleotidase) is in opposite directions in each knockout; and no clear roles in cancer 
for any of these genes have been reported. A possibility that we cannot exclude at this 
stage is that both CDK8 and CDK19 are required for transcription or repression of 
genes whose expression is only activated upon growth in foci. However, the minimal 
effects of deletion of either gene in shaping the transcriptome induced by expression 
of oncogenic Ras suggests that neither kinase is required to implement large-scale 
changes to gene expression, and that non-transcriptome effects should be considered. 
We suggest an alternative model, which is compatible with both apparent 
oncogenic activity of Mediator kinases in some circumstances and lack of effects in 
others. In this model, CDK8/19 are not in themselves oncogenes and therefore their 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/789586doi: bioRxiv preprint first posted online Oct. 1, 2019; 
overexpression does not transform cells, but rather provides a favorable terrain 
enabling the initiation of tumorigenesis by additional oncogenic factors, including bona 
fide oncogenes. For example, it is well established that, rather than transforming cells 
directly, expression of strong oncogenes such as RasG12V promotes premature cell 
senescence with accumulation of p53 and p16 (49). BMEL cells are immortal, but have 
a functional wild-type p53 (50). In this context CDK8/19 expression may attenuate the 
function of p53, thus unleashing the oncogenic potential of mutant Ras. We speculate 
that loss of p53 by mutation “fixes” the initial advantage conferred by overexpression 
of CDK8/19. This agrees both with our finding that in the liver, CDK8/19 are only 
required for cell transformation in the presence, but not the absence, of p53, and with 
the genetic interaction between CDK8/19 and TP53 in patients.  If such a scenario was 
indeed true, it would suggest a therapeutic niche for CDK8/19 kinase inhibitors in 
cancer: they would be expected to trigger differentiation or death of tumor cells that 
have not yet acquired p53 mutations. Our results warrant further investigation of 
CDK8/19 inhibitors as therapeutic agents for p53-positive hepatocellular carcinoma. 
 
Material and Methods 
Patients 
A total of 268 fresh-frozen tissue samples of HCC, associated with various etiologies, were 
included in this study. Patients and tumor features were already described in previously 
published studies and summarized in Supplemental Table 1. Written informed consent was 
obtained from all subjects in accordance with French legislation. 
CDK18 and CDK19 mRNA expression levels were assessed by quantitative RT-PCR using 
Fluidigm 96.96 Dynamic Arrays and specific TaqMan predesigned assays (CDK8= 
Hs00176209_m1; CDK19= Hs00292369_m1; Life Technologies, Carlsbad, CA). Data were 
calibrated with the RNA ribosomal 18S and changes in mRNA expression levels were 
determined using a comparative CT method using 5 normal tissue samples as control. 
 
Mice experiments 
All reported animal procedures were carried out in accordance with the rules of the French 
Institutional Animal Care and Use Committee and European Community Council 
(2010/63/EU). Animal studies were approved by institutional ethical committee (Comité 
d’éthique en expérimentation animale Languedoc-Roussillon (#36)) and by the Ministère de 
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l’Enseignement Supérieur, de la Recherche et de l’Innovation (D. Gregoire: APAFIS#11196-
2018090515538313v2).  
Cdk8F/F mice were generated as following: An 8076 bp genomic fragment (mouse chromosome 
5: 146,254,503 to 146,262,579) enclosing the essential exon 2 (whose deletion results in loss 
of the essential catalytic lysine residue and causes a frameshift truncating over 90% of the 
protein) of the CDK8 gene was amplified by PCR from genomic DNA of 129/Sv embryonic 
stem cells and cloned into pGEM-T-easy. The diphtheria toxin A gene was cloned into the 
SacII site. 64 bp to the 3’ of exon 2, the sequence CTCTAT was mutated to CTCGAG, 
generating an XhoI site. LoxP sites flanking exon 2 were generated by a combination of 
conventional cloning and recombineering, using an approach published in Liu et al., Genome 
Res. 2003 Mar;13(3):476-84. The loxP PGK-Neo cassette was amplified from pL452 plasmid 
with flanking AvrII/HindIII sites at each end and cloned into the AvrII site upstream of exon 2. 
Fragment orientation was confirmed by the generation of 3.5 kb HindII and 2.0 kb NheI sites, 
and the vector was recombined in E.coli strain SW106 with inducible Cre recombinase 
expression followed by HindII digestion, generating a single loxP site upstream of exon 2. Into 
this recombined vector, the FRT-PGK-Neo-FRT-LoxP cassette (amplified from pL451 with 
flanking XhoI sites) was cloned in the newly generated XhoI site downstream of exon 2, 
resulting in the “deletion construct”. The orientation was confirmed by the generation of 2.2 kb 
Nhe1 and 3.4 kb BamHI sites. Functionality of the two recombination sites was tested as 
follows: the FRT site was confirmed by recombination in E.coli strain SW105 with inducible 
FlpE recombinase expression, deleting the FRT-Neo cassette and generating a 1.4 kb BamHI 
fragment; and the resulting plasmid was transformed in E.coli strain SW106 with inducible Cre 
recombinase expression, deleting exon 2 and resulting in a 1.1 kb BamHI fragment. The NotI 
linearized fragment of the deletion construct was transfected by electroporation into 129/Sv 
embryonic stem cells. 244 Neomycin-resistant colonies were genotyped by PCR and Southern 
blotting. Two probes were used: one outside the 3’ end of the deletion construct, with HindIII 
digestion giving a single 9kb fragment for the WT and a 7kb fragment for the correctly-
integrated deletion cassette, and one to the 5’ end of the deletion cassette, again giving the 
same 9kb fragment for the WT but a 3.5 kb fragment for the deletion cassette. 10 colonies 
showed a correct integration by homologous recombination. These ES cells were injected into 
blastocysts obtained from pregnant Balb/c mice, and chimeric mice were crossed with 
C57/Bl6J mice constitutively expressing FlpE recombinase, removing the FRT-Neo cassette. 
Agouti mice were genotyped by PCR, showing correct insertion of the loxP sites around exon 
2. Alb-Cre mice were described previously (29). 
Allografts: Athymic Nude mice (Hsd:Athymic Nude-Foxn1nu, Envigo) or CDK8F/F mice were 
anesthetized with intra-peritoneal injection of Xylazine-Ketamine mixture. After incision of 
abdominal wall and peritoneum, the left lateral lobe of the liver was pulled out of the mouse 
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body. 50000 cells, resuspended in 5 μL of 25% Matrigel (BD) - PBS, were injected using a 
10μL Hamilton syringe in the left lobe of the liver. After injection, liver was put back in normal 
position and the abdomen was sutured. Tumors were allowed to grow out for 4 weeks, then 
collected and fixed following classical procedures. 
DEN induced carcinogenesis: Diethylnitrosamine (DEN) (30 mg/kg) was injected intra-
peritoneally in 14 days old male mice. Mice were sacrificed and livers collected after a period 
of 8 months. 
Hydrodynamic Gene Delivery: Hydrodynamic injections were performed in 6-8 week-old 
female mice as described previously (35). Briefly, 0.1 mL/g of a solution of sterile saline (0.9% 
NaCl) containing plasmids of interest were injected into lateral tail vein in 8-10 s. 
LentiCRISPRv2-sgTp53 (12.5 µg) and pT3-EF1a-N-RASG12D-GFP (12.5 µg) were injected 
together with sleeping beauty transposase SB100X (2.5 µg, ratio of 5:1). pCMV(CAT)T7-
SB100 was a gift from Zsuzsanna Izsvak (Addgene plasmid # 34879). 
  
Cell lines 
BMEL (Bipotential Mouse Embryonic Liver) cell line was isolated from CDK8F/F mouse. Cells 
were grown on collagen-coated plates in RPMI medium (Gibco/Life Technologies) 
supplemented with 10% fetal calf serum (Pan-Biotech), insulin 10  µg/mL (Sigma), IGFII 30 
ng/mL (Peprotech), EGF 50 ng/mL (Peprotech), 100 units/ml penicillin, and 100 mg/ml 
streptomycin. Other cell lines used, HepG2, Huh7, and HEK293T, were grown in Dulbecco 
modiﬁed Eagle medium (DMEM–high glucose, pyruvate, GlutaMAX–Gibco® LifeTechnologies) 
supplemented with 10% fetal bovine serum (Pan-Biotech). Cells were grown under standard 
conditions at 37°C in a humidiﬁed incubator containing 5% CO2. All cells were routinely tested 
to confirm absence of mycoplasma contamination. 
 
Generation of cell lines  
pMSCV retroviral vectors (Clontech) encoding CRE recombinase, tamoxifen-inducible CRE-
ERT2 (addgene plasmid #22776) or human H-RasG12V were used to generate stable BMEL 
cell lines. For induction of CRE-ERT2 activity, 4-OH tamoxifen was added to culture medium 
at a concentration of 2 µM for two weeks. CRISPR subgenomic RNA (sgRNA) targeting murine 
or human Cdk8, Cdk19 or Trp53 (CDK8 Mouse: 5’-ATCCCTGTGCAACACCCAGT-3’. 
CDK8_Human 5’-CGAGGACCTGTTTGAATACG-3’ CDK19_Mouse: 5’- 
AAAGTGGGACGCGGCACCTA-3’,  CDK19_Human, 5’-ATTATGCAGAGCATGACTTG-3’ 
Trp53 5’-ATAAGCCTGAAAATGTCTCC-3’   ; all sequences from Zhang lab database) were 
cloned as synthetic dsDNA into lentiCRISPRv2 vector as described (51) (provided by F. 
Zhang, Addgene plasmid #52961). Generation of lentiviral particles and infection of BMEL, 
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Huh7 or HepG2 cells were carried out following classical procedures, and described previously 
(52). Successfully infected cells were selected with puromycin (2 μg/mL) or hygromycin (150 
μg/mL) during 48h. Cell lines were further propagated and transgene expression or effects of 
targeted deletions verified by Western blot. Polyclonal cell lines were used for all subsequent 
experiments. 
 
Soft agar 
105 cells for each cell line were mixed with medium supplemented with 0.5% agarose and 
placed on top of the 1% agarose layer. 1 mL medium was added to the solidified layer and 
changed every 2-3 days. After 4 to 6 weeks, soft agar was stained with crystal violet 0,005% 
in 4% PFA for 1h. Colonies visible to the naked eye were counted manually.  
 
Immunohistochemistry 
Livers were fixed for 24 h in 10% neutral buffered formalin, embedded in paraffin, sectioned at 
4 μm and stained with haematoxylin-eosin safran (HES) or subjected to immunohistochemical 
staining. Immunohistochemistry staining of GS (BD Transduction Laboratories, 610517, 1:200) 
and CDK8 (Santa Cruz, sc-1521, 1:400) were performed using classical procedures, with 
antigen retrieval in citrate buffer, and biotinylated secondary antibody coupled to streptavidin–
peroxidase complex (ABC Vectastain kit; Vector Laboratories). Slides were digitally processed 
using the Nanozoomer scanner (Hamamatsu). 
 
Protein isolation and Western blotting  
Protein lysates of cells or tissues were prepared with lysis buffer (150mM NaCl, 50mM Tris pH 
7.5, 0.2% Triton, 1mM EDTA; freshly added 1mM DTT and protease inhibitors cocktail 
(Roche)) and incubated on ice for 30 min. Samples were centrifuged for 10 min at 13000rpm 
and supernatant collected. Protein concentrations were determined by BCA protein assay 
(Pierce Biotechnology). All the samples were mixed 1:1 with Laemmli buffer and heated at 
95°C for 5 min. Equal amounts of proteins were separated by SDS–PAGE (Biorad; usually 
12% gels). Proteins were transferred onto PVDF membranes (Milipore). Red ponceau or 
amidoblack staining was done to check transfer efficiency and equal amount of protein loading. 
Primary antibodies used were: Cdk8 (Santa Cruz #sc1521, dilution 1:1000); Cdk19 (Abcam, 
dilution 1:1000); p53 (Cell signalling #2524 1:1000), Actin (Sigma A1978, 1:20000), Tubulin 
(DSHB, 1:400). Antibodies were diluted in 5% BSA in TBS-Tween and incubated overnight at 
4°C. Secondary antibodies were either anti-goat IgG-HRP or anti-mouse antibodies IgG-HRP 
(Jackson immunoresearch). Band intensities were calculated using imageJ Lane Analysis. 
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RNA isolation, qPCR and RNA-Seq analysis  
The RNA was extracted from either cells or liver tissue and purified using RNeasy mini kit 
(Qiagen) according to manufacturer’s protocol. Reverse transcription of total RNA (1μg) was 
done with QuantiTect Reverse Transcription kit (Qiagen), and cDNA quantified using LC Fast 
stard DNA Master SYBR Green I Mix (Roche) with primers detailed below on LightCycler480 
apparatus (Roche). Gene expression levels were normalized with hypoxanthine phospho-
ribosyltransferase (HPRT). Primer pairs used for qPCR: Cdk8 5’- 
GAATTTCTATGTCGGCATGCAG-3’ and 5’-ATAGTCAAAGAGAAGCCATACTTTCC-3’, Glul 
5’-TAGCTGTCACAAAGCGGGTGTA-3’ and 5’-AGTGGAAATGTCAATCTCAGCC-3’, Axin2 
5’-ACCGGTCACAGGATGTC-3’ and 5’-GACTCCAATGGGTAGCTCTTTC-3’, c-myc 5’- 
CCGAGTGCATTGACCCCTCA-3’ and 5’- GAGAAGGCCGTGGAATCGGA-3’. Hprt 5’- 
GCAGTACAGCCCCAAAATGG-3’ and 5’-GGTCCTTTTCACCAGCAAGCT-3’. 
 For RNA-Seq analysis, RNA was extracted from exponentially growing subconfluent BMEL 
cells in three independent experiments for each cell line, using RNeasy mini kit (Qiagen) with 
DNAse treatment. RNA integrity was validated using RNA BioAnalyzer  (Agilent), all RIN ³ 9.5. 
The preparation of the library was done with the TruSeq Stranded mRNA Sample Preparation 
kit (Illumina). The sequencing was performed in an Illumina Hiseq 2500 sequencer by 
the Sequencing Platform of Montpellier (GenomiX, MGX, France; www.mgx.cnrs.fr), with 50 
base pairs (bp) single end reads to an estimated depth of 25 million reads per sample. In order 
to perform a quality control of the sequencing, FastQC over the fastq files containing the raw 
reads. All the reads that passed the quality control were aligned to the mouse reference 
genome (GRCm38.p6) and the counts per gene were quantified using the tool STAR 2.6.0a(2). 
The Ensembl mouse genome annotations (release 93) were used for establishing the 
coordinates of each gene and their corresponding transcripts.  Differential gene expression 
analysis was performed in R using the DESeq2 library. After normalization of the read counts 
per gene, a negative binomial generalized linear model was fitted considering single factor 
design for assessing the differential expression between CDK8/CDK19 knock-out BMEL 
RasG12V transformed cells and BMEL RasG12V transformed cells (as the control group). Wald 
test are performed for assessing statistical significance on the differential expression of each 
gene, then test are independently filtered and corrected by multiple hypothesis testing 
(Benjamini–Hochberg).  
 
Statistical Analysis 
Data sets were tested with 2-tailed unpaired Student t tests or Mann-Whitney U tests, 
correlations were analyzed with Pearson's χ2 test using Prism Software version 8 (GraphPad). 
Significant P values are shown as: *P <0.05, **P <0.01, ***P <0.001, and ****P <0.0001. 
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Human samples: Data visualization and statistical analysis were performed using R software 
version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria. https://www.R-
project.org) and Bioconductor packages. Comparisons of the mRNA expression levels 
between groups were assessed using Mann-Whitney U test. Spearman's rank-order 
correlation was used to test the association between continuous variables. Univariate survival 
analysis was performed using Kaplan-Meier curve with log-rank test. The median CDK8 and 
CDK19 expression levels on the total number of analyzed samples was used to determine the 
low- and high- expression groups. P-value < 0.05 was considered as significant. 
 
Data availability 
The RNA-sequencing data have been deposited in the Gene Expression Omnibus (GEO, 
NCBI) repository.  
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Figure 1: CDK8 and CDK19 are highly expressed in human HCC and associated with mutated p53 status. (A) 
Levels of CDK8 and CDK19 mRNA quantified by qPCR in control liver, non-tumoral part or malignant (HCC) tumor of 
patients. The fold change (LogFC) in gene expression is presented relative to mean expression level of the correspon-
ding gene in five normal liver samples. Data are represented as Tukey’s boxplots where box indicates the first and third 
quartiles, bar indicates median, whiskers indicate 1.5 interquartile range (IQR).  P-values obtained with the Wilcoxon 
rank-sum test are indicated. (B) Correlation between the expression of CDK8 and CDK19 mRNA levels in human HCC 
samples (n=268) using Spearman's rank-order correlation (C-F) Levels of CDK8 and CDK19 mRNA in HCC classified 
according to molecular classification of HCC (Boyault et al., 2007), mutated status of p53, 5 gene score (Nault et al., 
2013), or presence of macroscopic vascular invasion (histological identification), respectively. The number of patients in 
each class is indicated. The fold change (LogFC) in gene expression is presented relative to mean expression level of 
the corresponding gene in five normal liver samples. Data are represented as Tukey’s boxplots where box indicates the 
first and third quartiles, bar indicates median, whiskers indicate 1.5 interquartile range (IQR).  P-values obtained with the 
Wilcoxon rank-sum test are indicated. (G) Kaplan-Meier plots of overall survival in HCC patients (from(Nault et al., 
2013)) with high or low expression of CDK8 or CDK19 mRNA. High/low expression groups were defined by the median 
expression levels of the total number of analyzed samples. Statistical differences were assessed by Log-rank Test. 
P-value obtained are indicated.
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Figure 2: Hepato-specific ablation of CDK8 does not affect liver homeostasis, but induces stea-
tosis. (A) Map of CDK8 genomic locus and strategy used to generate CDK8F/F transgenic mouse. See 
material & methods section for details. (B) qPCR, Western-blot and immunohistochemical analysis of 
CDK8 removal in hepatocytes of CDK8ΔHEP mice. For qPCR quantification, males and females mice of 
different ages were used. CDK8 F/F (n=34) or CDK8ΔHEP (n=30). WB and IHC show results for  3 month 
old female mice. No differences were observed depending on sex or age of the animal. (C) HE staining 
of, GS staining, and qPCR analysis of β-catenin target genes (Glul, axin2, c-myc) in wild-type and 
CDK8 depleted 3 months old mice. n.s: not significant (t-test). (D) Body weight and steatosis grade 
score of 6 months old CDK8F/F and CDK8ΔHEP female mice. P value of Fisher’s exact test is indicated. 
Representative liver sections (HES staining) of mice from both genotypes are shown. 
CTCTAT mutated to CTCGAG
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Figure 3: CDK8 is required for hepatic carcinogenesis. (A) Effect of CDK8 depletion on DEN-induced hepa-
tic carcinogenesis. Pictures of representative livers for each genotype are shown. Arrowheads indicate tumors. 
Graph represents the repartition of the 28 DEN-injected animals, in each genotype depending if the liver 
presents a visible tumor (T) or not (NT). P-value of Fisher’s exact test is indicated. (B) Pictures and growth 
curve of CDK8F/F hepatic progenitors (BMEL) WT or depleted of CDK8 by CRE recombination. (C) Soft agar 
growth of different BMEL cell lines. A representative well for each cell line is shown. Mean number of colonies 
per well ± SD from at least three independent experiments are indicated. Tamoxifen treatment (+Tam) was 
realized before or after transformation induced by H-RasG12V expression. (D) Result of orthotopic allografts of 
Ras expressing BMEL depleted or not of CDK8. A representative liver is shown, and the number of livers 
carrying a tumor out of total liver injected is indicated. Arrowhead points out to the tumor. (E) Western-blot 
characterization of CDK8 removal by crispr/cas9 gene editing and consequences on growth in soft agar for 
BMEL (left panel) and HepG2 (right panel) cells. Asterisk indicates an aspecific band sometimes detected in 
BMEL cells. Mean ± SD number of colonies per well from at least three independent experiments are indicated.
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Figure 4: p53 deficiency abrogates CDK8 requirement for hepatic transformation. (A) Western Blot and quantifi-
cation of p53 protein levels in BMEL cell lines, showing stabilization of p53 in absence of CDK8.  A representative wes-
tern blot and quantification from 4 independent experiments (mean ± SD) are shown. For each experiment, the band 
intensity value of the CDK8F/F sample was normalized to 1. P-value from one-sample t test is indicated. (B) Soft agar 
test for indicated BMEL cell lines. (C) Hydrodynamic gene delivery of N-RasG12D and crispr-p53 vectors into livers of 
CDK8F/F or CDK8ΔHEP  female mice. Representative HES staining of tumors are shown. For each genotype, number or 
mice presenting liver tumors out of number of mice injected is indicated. (D) orthotopic allografts of tumor cell lines 
derived from CDK8F/F or CDK8ΔHEP  Ras crispr-p53.  White dashed lines indicated tumor periphery. Representative 
HES staining of tumors are shown. For each genotype, number or mice presenting liver tumors out of number of mice 
injected is indicated.
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Figure 5: CDK19 and CDK8 are both required for transformation by H-RasG12V . (A) Pictures, western blot and quanti-
fication of BMEL cell lines depleted of CDK19 by crispr/Cas9. A representative western blot and quantification from 4 
independent experiments (mean ± SD) are shown. * indicates an aspecific band sometimes detected with CDK8 antibo-
dy. For each experiment, the band intensity value or cDNA content of the crispr-Ctl sample was normalized to 1. P-value 
from one-sample t test is indicated. (B) Soft agar test for indicated BMEL cell lines. A representative well for each cell line 
is shown. Mean number of colonies per well ± SD from at least three independent experiments are indicated. (C) Heat-
map for the RNASeq experiments. The raw counts were transform using the regularized log and the variance was calcu-
lated between all the samples for all the genes. We selected the 100 genes with the higher variance. Distance between 
genes and samples were computed using the euclidean measure and the hierarchical cluster analysis was perform in 
order to set the distance trees. Two level of colors were set to describe the sample genotypes for RAS transformation 
(Violet: wild type; Blue: RASG12V mutation) and for Cdk8 or Cdk19 knock-outs (Gray: Control; Green: Cdk8 KO; Orange: 
Cdk19 KO). (D) Volcano plots for the differential gene expression. The values of the minus logarithm in base ten versus 
the logarithm in base two of the counts are plotted for each gene and two levels of significance are showed in red (genes 
with adjusted p-value less than 0.05) and in purple (genes with adjusted p-value less than 0.05 and with absolute values 
of the log2 of the fold change greater than one).
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